SecBot SecBot

INO drug pipeline

$1.40
−2.1% 1-day · Nov 16
Next catalyst
None dated
No dated FDA catalyst on file
Typical move on FDA news
±6.8%
1-day, median of 13 events
IV rank
No data
No current options data
Rated drugs
1
1 neutral
Phase 3 trials
0
0 with results posted

Upcoming catalysts

1 dated
  1. Dec 31, 2026
    INO-5401
    Phase 2 primary completion

Drugs

soonest catalyst first
● neutral
Impact
PhaseApproved (Accelerated Approval)
Time to marketAlready approved (October 30, 2026). Commercial launch expected in Q1 2027, with initial ordering and shipping in approximately 60 days.

VOCERYQ doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd Updated Nov 2

What to watch

With the approval binary resolved, the next key events are the confirmatory study protocol submission (due end of 2026, final by mid-2027) and the commercial launch in Q1 2027. Monitor initial prescription uptake and payer coverage in the first two quarters post-launch, as Inovio's cash runway extends only into late Q1 2027, leaving little margin for a slow commercial start.

Bull case
  • VOCERYQ is the first FDA-approved DNA medicine in U.S. history, validating Inovio's plasmid DNA platform and opening a potential pipeline value for other candidates.
  • It targets a U.S. prevalent population of at least 25,000 RRP patients who previously had no non-surgical option until Papzimeos in 2025; a second therapy expands the market and gives physicians a differentiated mechanism (DNA vs. adenoviral).
  • Analyst consensus is bullish: 5 of 7 analysts rate Buy or Strong Buy, with a mean price target of $3.17 (vs. ~$2.23 pre-market), and HC Wainwright upgraded from Neutral to Buy on Nov 2.
Bear case
  • Accelerated approval rests on a single-arm, open-label Phase 1/2 study of just 32 patients; only 27% (7/26) of evaluable patients achieved the complete response of no surgery for 12 months, a modest efficacy signal.
  • Continued approval is contingent on a confirmatory study. Inovio must submit a draft protocol by end of 2026 and finalize by mid-2027; failure to verify clinical benefit could lead to withdrawal.
  • Inovio faces entrenched competition from Precigen's Papzimeos, approved in August 2025 as the first RRP therapy, which already generated $74.7M in sales and has a head start in the laryngologist prescriber base.

Other drugs in filings and trials

no drug report yet
  • HPV DNA Plasmids Therapeutic Vaccine VGX-3100 1 trial

Past FDA events & how the stock moved

13 events
DateDrugEvent1 day5 days
Oct 30, 2026VOCERYQPDUFA decision+145.4%—
Oct 30, 2026VOCERYQApproval+145.4%—
Oct 30, 2026VOCERYQAdCom meeting+145.4%—
Jun 30, 2026VOCERYQAccelerated approval+6.3%+8.0%
Dec 31, 2025VOCERYQBLA filed−4.0%−8.5%
Dec 31, 2025VOCERYQPriority review−4.0%−8.5%
Dec 29, 2025VOCERYQBLA filed−23.1%−30.1%
Dec 29, 2025VOCERYQAccelerated approval−23.1%−30.1%
Dec 1, 2025VOCERYQPriority review−6.8%+1.5%
Dec 1, 2025VOCERYQAccelerated approval−6.8%+1.5%
Dec 1, 2025VOCERYQBLA filed−6.8%+1.5%
Nov 10, 2025VOCERYQBLA filed−5.7%−6.6%
Nov 10, 2025VOCERYQPriority review−5.7%−6.6%

Clinical trials

4 Phase 2/3
DrugTrialPhaseStatusEnrolledPrimary completion
INO-5401INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM)Phase 2Active not recruiting52Dec 31, 2026
INO-5401INO-5401 + INO-9012 in Combination With Atezolizumab in Locally Advanced Unresectable or Metastatic/Recurrent Urothelial CarcinomaPhase 2Completed · results35May 9, 2025
HPV DNA Plasmids Therapeutic Vaccine VGX-3100VGX-3100 and Electroporation in Treating Patients With HIV-Positive High-Grade Anal LesionsPhase 2Completed · results44Dec 31, 2024
VOCERYQINO-3107 With Electroporation (EP) in Participants With HPV-6- and/or HPV-11-Associated Recurrent Respiratory Papillomatosis (RRP)Phase 2Completed · results32Dec 15, 2022